
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
As attendees crowded the Exhibit Hall during the AAP Meeting, Contemporary Pediatrics captured the crowd.
As people crowded the Exhibit Hall during the AAP Meeting, Contemporary Pediatrics captured the scene.






